Rituximab (MabThera®) subcutaneous formulation is indicated in adults for Non-Hodgkin’s lymphoma (NHL):
MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Rituximab |
| Brand | MabThera® |
| Indication | Is indicated in adults for Non-Hodgkin’s lymphoma (NHL): Is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy: As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy: For the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 26/05/2014 |
| Rapid review completed | 22/09/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |
